2025-2026 Regular Session • US Congress Legislature
SB1414
Legislative Summary
A bill to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.
Bill History
4/10/2025
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Senate
Status Information
Current Status
Introduced(4/10/2025)
Chamber
Senate
Committee
Health, Education, Labor, And Pensions(Senate)
Sponsors
Republican: 1
Primary Sponsor
Rand Paul
Republican